Economic and clinical outcomes of pegfilgrastim via prefilled syringe vs on-body injector: a real-world data analysisAli McBride, Weijia Wang, Edward Li et al.|Journal of Managed Care & Specialty Pharmacy|2021Cited by 11
The effects of oral anticancer parity laws on out-of-pocket spending and adherence among commercially insured patients with chronic myeloid leukemiaAndrew Spargo, Joshua D. Brown, Aditya Raju et al.|Journal of Managed Care & Specialty Pharmacy|2021Cited by 5
The Impact of Baseline Risk Factors on the Incidence of Febrile Neutropenia in Breast Cancer Patients Receiving Chemotherapy with Pegfilgrastim Prophylaxis: A Real-World Data AnalysisEdward Li, Weijia Wang, Bridgette Kanz Schroader et al.|Journal of health economics and outcomes research|2021Cited by 2
The Impact of Baseline Risk Factors on the Incidence of Febrile Neutropenia in Breast Cancer Patients Receiving Chemotherapy with Pegfilgrastim Prophylaxis: A Real-World Data AnalysisEdward Li, Weijia Wang, Kim Campbell et al.|Journal of health economics and outcomes research|2021Cited by 1